CATT AMD Report
New Questions on Avastin, Lucentis, VEGF Trap-Eye
By Tom Wall
Monday, May 2, 2011
Physicians, patients and analysts had new questions following the release of first-year results from a two-year National Institutes of Health study that found Avastin (bevacizumab), an FDA-approved cancer drug commonly used off-label, as effective as FDA-approved Lucentis (ranibizumab) in treating age-related macular degeneration (AMD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.